The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On March 30, BullFrog AI signed a commercial agreement with a top 5 global pharmaceutical company by revenue. The agreement utilizes the proprietary bfLEAP® platform to identify and prioritize therapeutic targets for Major Depressive Disorder (MDD). The MDD market was valued at over $8 billion in 2025 and is expected to exceed $11 billion by 2032.